Boston—Curing infection with the hepatitis C virus appears to dramatically improve five-year survival rates in people with liver cancer whose tumors are caused by the infection, a new study has found.
In light of the results, the researchers said patients with hepatocellular carcinoma (HCC) linked to HCV who are candidates for cancer treatment also should be considered for direct-acting antiviral (DAA) therapy.
“We feel that in patients with HCV-related HCC, direct-acting antivirals